Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 15Phase 1/2 14Phase EARLY_PHASE1 6Phase 3 6Phase NA 2Phase 4 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 505Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 117Neoplasms 67Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Interventions

olaparib 3Abiraterone Acetate 3enzalutamide 2Docetaxel 2radium Ra 223 dichloride 1darolutamide 1cabazitaxel 1Prednisone 1Prednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Metastatic Castration-resistant Prostate Cancer × Genitourinary × Clear all
NCT03732820 2026-06-02

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

AstraZeneca

Phase 3 Active not recruiting
895 enrolled 19 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

BioNTech SE

Phase 3 Recruiting
736 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02044354 2026-04-01

CABA-DOC

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
195 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

AstraZeneca

Phase 3 Active not recruiting
110 enrolled 12 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

AstraZeneca

Phase 3 Completed
387 enrolled 16 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04237584 2022-10-07

ESCALATE

MANA RBM

Phase 3 Terminated
23 enrolled 11 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡